Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms-Reference-Cited by-同舟云学术

Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms

Published:2018-12 Issue: Volume:228-229 Page:197-217
ISSN:2210-7762
Container-title:Cancer Genetics
language:en
Short-container-title:Cancer Genetics

Author:

Kanagal-Shamanna Rashmi^ORCID,Hodge Jennelle C.,Tucker Tracy,Shetty Shashi,Yenamandra Ashwini,Dixon-McIver Amanda,Bryke Christine,Huxley Emma,Lennon Patrick A.^ORCID,Raca Gordana,Xu Xinjie^ORCID,Jeffries Sally,Quintero-Rivera Fabiola,Greipp Patricia T.,Slovak Marilyn L.,Iqbal M. Anwar,Fang Min

Publisher

Elsevier BV

Subject

Cancer Research,Genetics,Molecular Biology

Reference118 articles.

1. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia;Arber;Blood,2016

2. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge;Schanz;J Clin Oncol,2012

3. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997

4. Revised international prognostic scoring system for myelodysplastic syndromes;Greenberg;Blood,2012

5. Myeloproliferative Neoplasms, Version 2.2017, NCCN clinical practice guidelines in oncology;Mesa;J Natl Compr Canc Netw,2016

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytogenetics in the management of hematological malignancies: An overview of alternative technologies for cytogenetic characterization;Current Research in Translational Medicine;2024-09

2. Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives;Cancers;2024-04-15

3. Section E6.1–6.6 of the American College of Medical Genetics and Genomics (ACMG) Technical Laboratory Standards: Cytogenomic studies of acquired chromosomal abnormalities in neoplastic blood, bone marrow, and lymph nodes;Genetics in Medicine;2024-04

4. Comprehensive Study of Chromosomal Copy Number Variations and Genomic Variations Predicting Overall Survival in Myelodysplastic Syndromes;Oncology;2024-03-05

5. JAK2 V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes;Blood Advances;2023-12-14